Paradigm Biopharmaceuticals Ltd has released a press release.
Phase 2 Synovial Fluid Biomarker Study Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Positive top-line results from preclinical study in ards
- First mps-vi patient dosed under phase 2 trial in Brazil
- Paradigm receives feedback from US FDA on ind submission
- Aus ethics approval received for phase 3 trial
- 2021 Annual Report and Appendix 4E
Later from Paradigm Biopharmaceuticals
- Paradigm cleared for phase 3 trial by US FDA
- Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
- Preliminary Results from Phase 2 MPS I Study
- PAR reports postive topline results in heart failure model
- Paradigm treats first subjects in phase 3 trial of zilosul
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals